论文部分内容阅读
目的探讨低分子肝素钙治疗小儿紫癜性肾炎的临床疗效及相关分析。方法 2009年10月至2011年10月期间,我院诊治的40例小儿紫癜性肾炎患者,随机将其分为对照组(常规治疗)和观察组(加低分子肝素钙),每组各20例,对两组患者的临床疗效、血凝学指标进行观察和比较。结果 20例对照组患者中,完全缓解5例,部分缓解8例,无效7例;20例观察组患者中,完全缓解11例,部分缓解7例,无效2例。与对照组相比(65.0%),观察组的有效率明显升高(90.0%),P<0.05。两组患者都仅出现注射部位轻度淤斑,没有出现其他的严重不良反应。结论对于小儿紫癜性肾炎患者,低分子肝素钙明显提高临床疗效,并且不良反应少。
Objective To investigate the clinical effect and related analysis of low molecular weight heparin calcium in children with purpuric nephritis. Methods From October 2009 to October 2011, 40 children with purpura nephritis diagnosed and treated in our hospital were randomly divided into control group (conventional treatment) and observation group (plus low molecular weight heparin) with 20 Cases, the clinical efficacy of two groups of patients, hemagglutination indicators were observed and compared. Results Among the 20 patients in the control group, 5 were completely relieved, 8 were partially relieved, and 7 were ineffective. Among 20 patients in the observation group, 11 were completely relieved, 7 were partially relieved, and 2 were ineffective. Compared with the control group (65.0%), the observation group was significantly higher (90.0%), P <0.05. Both groups showed only mild ecchymoses at the injection site and no other serious adverse reactions occurred. Conclusion For patients with purpura nephritis in children, low molecular weight heparin calcium significantly improve clinical efficacy, and less adverse reactions.